PolyPid to Present at the Barclays Global Healthcare Conference

PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.

Barclays Global Investor Conference:

Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.

About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: PolyPid, Ltd. Ori WarshavskyCOO – US OperationsTel: +1-908-376-6758

Investors:Brian RitchieLifeSci Advisors212-915-2578[email protected]

You May Also Be Interested In

• Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
• Form 8.3 - LondonMetric Property Plc & Schroder Real Estate Investment Trust Limited
• Form 8.3 - Advanced Medical Solutions Group